

# The Neurotoxic Effects of Cannabis on Brain: Review of Clinical and Experimental Data

OMAR M.E. ABDEL-SALAM

Department of Toxicology and Narcotics, Medical Research and Clinical Studies Institute, National Research Centre, Tahrir Street, Cairo, EGYPT

**Abstract:** - Cannabis is the most widely used illicit drug worldwide. Evidence indicated negative impact for cannabis on the brain. Animal research and in vitro studies using delta-9-THC (THC) or cannabis extracts with high THC content provided evidence for a detrimental effect on neuronal integrity with DNA damage, cell shrinkage, atrophy and apoptosis. The mechanisms by which herbal cannabis affects brain structure and function are not clear but impaired mitochondrial functioning, reduced glucose availability and inhibition of brain energetic metabolism by cannabis have been shown. Clinical studies investigating the effects of cannabis in humans found raised serum levels of proinflammatory cytokines in chronic cannabis users. Human studies also indicated increased oxidative stress biomarkers and reduced antioxidants in blood of chronic cannabis users. Preclinical data on the effect of cannabis or THC on oxidative stress, however, were less conclusive in that cannabis might increase or attenuate oxidative stress and neurotoxicity. The aim of this review is to summarize the evidence from animal and clinical studies pertaining to the toxic effects of cannabis and its main psychoactive ingredient THC on the brain and possible mechanisms involved.

**Key-Words:** - delta-9-tetrahydrocannabinol; brain; cannabis; oxidative stress; neuroinflammation

Received: May 13, 2021. Revised: February 14, 2022. Accepted: March 12, 2022. Published: April 13, 2022.

## 1 Introduction

The psychoactive plant *Cannabis sativa* is the most widely used illicit drug worldwide, with an estimated 192 million people having used cannabis in 2018. Cannabis use is also on the rise with the increasing legalisation for medicinal and recreational use [1]. The term ‘marijuana’ or ‘marihuana’ refers to the flowering tops and leaves of the female plant while the resin obtained from these flowers is known as ‘hashish’ [2]. The chemistry of *Cannabis sativa* plant is complex with over 650 compounds and a group of a terpenophenolic compounds, unique to cannabis and known as cannabinoids [2,3]. To date, more than 120 cannabinoids have been described [4], the most abundant of them is the  $\Delta^9$ -tetrahydrocannabinol (THC) which is responsible for the psychomimetic effects that occurs when cannabis is smoked such as feelings of euphoria, distortion of time perception, altered sensory experiences, motor incoordination and impairments of memory [5,6]. Cannabidiol (CBD) is another cannabinoid present in small amounts in the cannabis plant, but is devoid of psychotropic effects and appears to antagonize some of the biological effects of THC. The latter exerts its effects by acting on two types of G-protein coupled receptors; cannabinoid CB1 and CB2

receptors [7]. CB1 receptors are abundant in brain areas associated with cognition, memory, learning, emotions, appetite, and motor coordination and mediate most of the central actions of cannabis in humans. CB2 receptors are mainly found on cells of the immune system in the periphery. There are also endogenous compounds, the endocannabinoids that can act on cannabinoid receptors eg., anandamide and 2-arachidonylglycerol [8].

The last decade has witnessed increasingly growing interest in using cannabis for treating a variety of medical conditions.. The inhalation of THC-containing cannabis was reported by patients with Parkinson’s disease [9], fibromyalgia [10], sickle cell disease [11], inflammatory bowel disease [12], neuropathic pain [13]. Formulations of whole plant extract containing 1:1 THC/CBD in the form of an oromucosal spray is used by patients with multiple sclerosis for improving spasticity [14] and bladder dysfunction [15].

There is evidence, however, that indicate a negative impact for cannabis on the brain on the short- and on the long-term [16,17]. Adolescents and young adults are particularly prone to the health hazards of cannabis with decline in IQ among cannabis users, impaired cognitive performance, lower academic

achievement and educational outcome with longer time to graduation [18,19]. Cannabis induces impairment of driving performance increasing road accidents [20]. Evidence links cannabis use to development of psychotic events late in life [21]. Users of cannabis might also suffer ischaemic stroke, more frequently in young men [22]. Neuroimaging studies of cannabis's influence on brain in humans have shown structural alterations indicative of neurotoxic effects [23]. The present review therefore aims to shed light on the consequences of cannabis use and its main psychoactive compound THC on brain neuronal integrity and the underlying mechanisms involved in neurotoxicity.

## 2 Evidence that Cannabis is Toxic to Cells

Animal research and in vitro studies using cannabis extracts rich in THC or its main psychotropic ingredient THC provided strong evidence for a detrimental effect for THC on neuronal integrity [24-28]. Sarafian et al. [25] found that exposing endothelial cells to smoke from marijuana cigarettes for 30 min induced a time-dependent increase in necrotic cell death that increased steadily reaching 78% at 48 h. In vitro studies using A549 cells, a human lung cancer cell line, showed that THC decreased in ATP levels with an IC<sub>50</sub> value of 7.5 µg/ml, decreased mitochondrial membrane potential (at concentrations of 2.5 or 10 µg/ml) as early as 1 h after exposure and caused cell death [26]. Zhu et al. [29] showed that treatment of murine ConA-activated splenocytes and LPS-activated peritoneal macrophages in culture with THC (10 µg/ml) increased DNA fragmentation. THC treatment decreased Bcl-2 mRNA and protein in splenocytes. THC-induced apoptosis was blocked by the caspase-1 inhibitor. Downer et al. [30,31] reported that THC-induced apoptosis of primary rat cortical neurons. The mechanism involved the activation of c-jun N terminal kinase, release of cytochrome c, activation of caspase-3, an increase in Bax expression, and cleavage of the DNA repair enzyme poly-ADP ribose polymerase. The THC-induced apoptosis was blocked by the CB (1) receptor antagonist AM-251. Gowran and Campbell [32] showed in addition that in primary cortical neurons, THC (5 µM) caused rapid, but transient, increase in lysosomal membrane permeability. This effect on lysosomal integrity occurred within 15 min after exposure to THC and was maintained for 30 min. THC-induced caspase-3 activation and

apoptotic cell death by evoking the release of the lysosomal cathepsin enzyme, cathepsin-D, into the cytosol. These effects of THC were CB-mediated and involved the tumour suppressor protein, p53.

Chan et al. [24] found that concentrations of THC as low as 0.5 µM were toxic to rat hippocampal neurons. Rat hippocampal slices were exposed to THC. The CA1 pyramidal cell layer of hippocampal slices exposed to THC exhibited condensed, contracted and smaller nuclei, shrinkage of neuronal cell bodies and genomic DNA breakage. Steel et al. [27] reported impaired hippocampal neuroplastic response, and new-born neurons induced by training in rats after intraperitoneal (i.p) injection of THC (6 mg/kg).

Studies in rats treated with THC (10 or 20 mg/kg orally) for 90 days revealed reduction in the dendritic length of CA3 pyramidal neurons. The higher dose of 60 mg/kg induced 44% reduction in the number of synapses per unit volume [33]. Landfield et al. [34] found decreased neuronal density and increased glial cell reactivity in the hippocampus of rats treated chronically THC for 8 months. Other studies investigated the effect of cannabis extracts containing 10% THC in vivo. Rats received cannabis extracts at doses of 5, 10 or 20 mg/kg (expressed as THC), i.p., once a day for 30 days. Brain sections showed the presence of dark neurons with small or undefined nuclei, cellular infiltration, and gliosis. Immunohistochemical staining with caspase 3 antibody, revealed increased number of positively reactive cells, indicative of apoptosis. Electron microscopy of a neuron from rats treated with 20 mg/kg cannabis, showed an elongated nucleus, discontinued nuclear envelope and dispersed rough endoplasmic reticulum. Cannabis caused DNA damage of polymorphonuclear leucocytes (PNL) evaluated by alkaline single cell gel electrophoresis (comet assay). The above effects of cannabis were dose-dependent [35]. Glial fibrillary acidic protein (GFAP) is a marker of reactive gliosis, a process, whereby, astrocytes became activated in response to brain injury [36]. Studies showed increased GFAP staining in the hippocampus and parietal cortex in rats treated with THC during adolescence [37]. Moreover, rats given cannabis extracts also showed significant increments in brain and serum levels of GFAP [38] (Table 1).

Table 1. In vitro and in vivo cellular toxic effects of THC or cannabis extracts

Experimental model	Toxic effect	Suggested mechanisms	Study
Endothelial cells exposed to marijuana smoke containing THC	↑ Necrotic cell death	↓ Cellular GSH ↑ ROS	[24]
A549 cells treated with THC (2.5 or 10 µg/ml)	↑ Cell death	↓ ATP ↓ Mitochondrial membrane potential	[25]
Rat hippocampal slices exposed to THC (0.5 µM)	↓ Size of neuronal cell bodies & Genomic DNA breakage		[26]
Murine ConA-activated splenocytes and LPS-activated peritoneal macrophages exposed to THC (10 µg/ml)	↑ DNA fragmentation Apoptosis	Caspase-1 mediated ↓ Bcl-2 mRNA and protein	[29]
Primary rat cortical neurons treated with THC	↑ Neuronal apoptosis	↑ Caspase-3 ↑ Bax expression ↑ c-jun N terminal kinase ↑ Cytochrome c	[30][31]
Primary rat cortical neurons treated with THC (5 µM)	↑ Apoptotic cell death	↑ Lysosomal membrane permeability ↑ Caspase-3 Release of the lysosomal cathepsin-D into the cytosol	[32]
Rats treated with THC (10 or 20 mg/kg orally) for 90 days	↓ Dendritic length of CA3 pyramidal neurons.		[33]
Rats treated with THC for 8 months	↓ Neuronal density in hippocampus	↑ Glial cell reactivity	[34]
Rats treated with cannabis extracts (10-20 mg/kg) THC for 4 weeks	↑ Dark neurons with small or undefined nuclei Cellular infiltration Gliosis ↑ DNA damage of PNL (comet assay).	↑ Caspase 3	[35]
Rats treated with THC during adolescence	↑ Glial fibrillary acidic protein (GFAP) staining in the hippocampus and parietal cortex		[37]
Rats treated with cannabis extracts (10-20 mg/kg) THC for 6 weeks	↑ Brain & serum GFAP		[38]

### 3 Cannabis in Animal Models of Brain Neurotoxicity

In an in vivo model of excitotoxicity induced by intracerebral injection of Na<sup>+</sup>/K<sup>+</sup>-ATPase inhibitor ouabain in neonatal rats, co-injection of THC (1 mg/kg, i.p.) exerted neuroprotective effects. Diffusion-weighted magnetic resonance imaging showed that THC reduced the volume of cytotoxic edema (neuronal swelling) 15 min after ouabain injection and the volume of infarcted tissue after 7

days. THC reduced neuronal damage via a CBR1-dependent mechanism [39].

Hayakawa et al. [40] suggested that acute but not chronic administration of THC protects against ischaemic brain injury. In this study, THC (3 and 10 mg/kg) and also cannabidiol significantly reduced the infarct volume induced by middle cerebral artery occlusion for 4h in mice. THC (3 and 10 mg/kg) was injected i.p. immediately before and 3 h after cerebral ischaemia. The neuroprotective effect of acutely administered THC was inhibited by CBR1 antagonist and is likely to involve an increase in

cerebral blood flow and hypothermic effect. In contrast to acute treatment, repeated i.p. injection of THC (10 mg/kg) for 14-day prior to cerebral ischaemia in mice significantly increased infarct volume.

In another study, transient global cerebral ischaemia was induced in rats by bilateral common carotid artery (CCA) occlusion for 45 minutes followed by 4 h of reperfusion. Cannabis extract was i.p. administered in a single dose of 20 mg/kg THC either before CCA, at time of reperfusion, after reperfusion or daily for 2 days before surgery. Cannabis was found to significantly increase GSH and to alleviate the increase in nitric oxide levels in the ischaemic brain tissue. Cannabis given before or at time of CCA occlusion also significantly reduced brain tumour necrosis factor- $\alpha$  (TNF- $\alpha$ ). Cannabis given as a single dose 1h before cerebral ischaemia or as two days pretreatment conferred histologic

protection against the ischaemic/reperfusion neuronal injury. In contrast, cannabis given at time of CCA occlusion exacerbated brain damage with widespread severe spongiform changes and neuronal loss [41].

Interestingly, cannabis resin extract was found to protect against neurotoxicity caused in the rat by the organophosphorus compound malathion. The extract was given at doses of 10 or 20 mg/kg (expressed as THC) 30 min prior to i.p. injection of malathion. Cannabis did not alter MDA level but prevented the depletion of in GSH and the decrease in paraoxonase-1 activity in the brain of malathion-treated animals. Spongiform changes, neuronal damage in cerebral cortex and the degeneration of Purkinje cells in cerebellum were prevented by cannabis 20 mg/kg [42]. Cannabis was shown to modulate the activities of cholinesterases in brain and serum of rats [43,44]. THC has also been reported to competitively inhibit acetylcholinesterase (AChE) by binding to the allosteric peripheral anionic binding site of the enzyme [45]. Several terpenoids in the plant *Cannabis sativa* e.g., pulegone, limonene, and limonene oxide were also shown to inhibit AChE in vitro [46]. THC and cannabis other constituents thus might act to prevent the irreversible binding of the organophosphate metabolites onto the AChE and thus prevent the malathion induced neurotoxicity [42].

Other studies, however, failed to demonstrate a neuroprotective effect for cannabis extracts on brain histology despite evidence of reduced brain

oxidative stress. One study investigated the effect of cannabis on  $AlCl_3$  neurotoxicity was at neurobehavioral, biochemical and histopathological levels.  $AlCl_3$  induced brain oxidative stress, a cognitive deficit detected by the water maze test and brain damage in the form of shrunken neurons with pyknotic nuclei and eosinophilic cytoplasm. Cannabis sativa extract (10 and 20 mg/kg THC) was given daily in combination with  $AlCl_3$  for 6 weeks. Cannabis significantly alleviated the increase in MDA, nitric oxide and the GSH depletion in brain of  $AlCl_3$ -treated rats. Cannabis, however, failed to alter the cognitive deficit or the damage in cerebral cortex and hippocampus induced by  $AlCl_3$  [47]. In the epilepsy model induced in rats by the GABA (A) receptor antagonist pentylenetetrazole (PTZ), cannabis treatment (20 mg/kg THC) caused significant elevation of seizure scores. In PTZ treated rats, cannabis resulted in significant increase in brain MDA. Histopathological changes induced by PTZ such as degenerated and necrotic neurons, inflammatory cells, and gliosis in cerebral cortex and cerebellar Purkinje cells degeneration were not improved by cannabis treatment [48]. In brain of thioacetamide-treated rats, the increments in MDA and nitric oxide were significantly decreased by cannabis (10 and 20 mg/kg THC). Brain sections from only thioacetamide-treated rats showed some neurons with dark small nuclei. Cannabis enhanced the damaging effect of thioacetamide with neurons showing ballooning and degeneration and increased number of neurons with dark nuclei [49]. Rotenone, a naturally occurring pesticide of plant origin [50] is used in rodents to model human Parkinson's disease [51,52]. In mice, daily i.p. injection of rotenone, the inflammogen LPS or their combination for 2 weeks increased oxidative/nitrosative stress in brain and induced nigrostriatal neuronal damage. Cannabis (20 mg/kg THC) s.c., co-injected with the toxicants, reduced brain oxidative stress but did not reduce neuronal damage [53]. In another study, cannabis resin extract was s.c. given for 2 days prior to and at the time of i.p. LPS endotoxin injection administration. Cannabis 20 mg/kg (expressed as THC) lessened the increase in MDA, nitric oxide and restored GSH levels in the brain of LPS-treated mice. Cannabis, however, increased histologic brain damage with cellular atrophy, shrinkage, necrosis, pyknosis, and deeply stained and dark nuclei being observed in sections from the cerebral cortex. Caspase-3 immunostaining was markedly increased in degenerating neurons of the cerebral cortex by LPS/cannabis compared with only LPS treatment [54].

## 4 Cannabis and Brain Oxidative Stress

Oxidative stress is the term applied to the situation in which the balance between reactive oxygen species (ROS) and antioxidant mechanisms in the cell is tilted in favor of the oxidant side. This occurs because of either too much ROS or insufficient antioxidants. The result is oxidative damage to cell biomolecules eg., membrane lipids, enzymes, and DNA, cell perturbation and even death [55]. Reactive species are produced within the cell during normal metabolism eg., the mitochondrial respiratory chain where the mitochondrial complexes I and III leak electrons to O<sub>2</sub> forming superoxide anion radical (O<sub>2</sub><sup>•-</sup>). Superoxide can then result in the formation of several intermediates such as hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>), and hydroxyl radical (OH<sup>•</sup>) or react with nitric oxide to generate the highly reactive peroxynitrite (ONOO<sup>-</sup>) [56,57]. The mitochondria is the major source for ROS in the cell but is also subject to attack by ROS that may cause mitochondrial dysfunction and initiation of cell death cascade [58] and mitochondrial dysfunction has been linked to aging and age-related neurodegenerative diseases [59,60].

### 4.1 Human Studies

There are few studies that have measured oxidative stress biomarkers in cannabis smokers. The effects of cannabis were studied by Toson [61] in a group of long-term marijuana smokers with smoking duration of 5-10 years. Compared to healthy controls, cannabis smokers had significant increase in blood malondialdehyde (MDA), a marker of lipid peroxidation. Serum levels of nitric oxide were markedly raised as well. Meanwhile, reduced glutathione (GSH) in blood, and the total antioxidants capacity (TAC) in serum were significantly reduced in cannabis users. Moreover,

serum C-reactive protein showed 40% increase in users of cannabis. Other researchers found significant increase in serum MDA and urinary 8-hydroxydeoxyguanosine (a biomarker of oxidative DNA damage) and decreased serum TAC in tobacco and tobacco/marijuana smokers compared to healthy controls [62]. Bayazit et al. [63] measured total antioxidant status, total oxidant status and proinflammatory cytokines levels in serum in patients with cannabis use disorder. Patients aged between 18 and 35 years of age and were using cannabis at time of study. Compared with their healthy controls, cannabis-dependent subjects exhibited significant increase in total oxidant status, and oxidative stress index. Moreover, there were significant increments in the interleukins 1 $\beta$ , 6, 8, and tumor necrosis factor- $\alpha$  in subjects with cannabis use disorder. Another study in patients with cannabis dependence reported a significant increase in lipid hydroperoxide, and decreased free thiol levels but increased brain-derived neurotrophic factor, and ceruloplasmin in serum [64].

In contrast to the above studies, Bloomer et al. [65] reported no significant effect for smoking marijuana on oxidative stress. In their study, young (23-24 years) frequent marijuana users and non-smokers participated in regular exercise and then tested for biomarkers of oxidative stress and cardio-metabolic health. Participants smoke marijuana on average of 4.5  $\pm$  2.3 sessions per week for at least three months before the study. The study found no significant differences in MDA or advanced oxidation protein produces in plasma of marijuana users compared with non-users which was explained by the beneficial effect of regular exercise on oxidative stress (Table 2).

Table 2. Human studies indicating increased oxidative stress or inflammatory markers in cannabis users

Oxidative stress biomarkers	Study
↑ MDA in blood ↑ Nitric oxide in serum ↓ GSH in blood ↓ TAC in serum	[61]
↑ MDA in serum ↑ Urinary 8-hydroxydeoxyguanosine ↓ TAC in serum	[62]
↑ Total oxidant status ↑ Oxidative stress index.	[63]
↑ Lipid hydroperoxide in serum ↓ Free thiols in serum	[64]

Inflammatory markers	
↑ C-reactive protein in serum	[62]
↑ IL-1β in serum ↑ IL-6 in serum ↑ IL-8 in serum ↑ TNF-α in serum ↑ Ceruloplasmin in serum	[63]

**Abbreviations:** MDA (malondialdehyde); GSH (reduced glutathione); TAC (total antioxidant capacity); IL-1β (interleukin-1beta); IL-6 (interleukin-6); IL-8 (interleukin-8); TNF-α (tumour necrosis factor- α).

#### 4.2 In Vitro Studies

Sarafian et al. [24] exposed endothelial cell line to smoke produced from marijuana cigarettes containing either 1.77 or 3.95% THC. Marijuana smoke from 3.95% THC cigarettes resulted in a rapid and sustained decrease in cellular GSH level by 83% after 10 min. Marijuana smoke (though not pure synthetic THC) increased ROS by 80%. Several research groups have shown that THC causes mitochondrial dysfunction and increase ROS. In isolated mitochondria extracted from rat brain, exposure to THC inhibited complexes I, II, and III of the mitochondrial respiratory chain and decreased mitochondrial coupling. THC enhanced H<sub>2</sub>O<sub>2</sub> production and mitochondrial free radical leak [28]. THC was also shown to deplete ATP, impair mitochondrial respiratory function, decrease mitochondrial membrane potential, increase cellular ROS and markers of lipid damage in human trophoblast cell lines. THC also increased mitochondrial fission and the expression of cellular stress markers, HSP70 and HSP60 [66].

In contrast, in vitro experiments in a Fenton reaction system, cannabidiol and THC were able to prevent Tert-butyl hydroperoxide-induced oxidation of dihydrorhodamine, an oxidation sensitive fluorescent dye. THC and cannabidiol were shown to equally protect rat cortical neurons in culture against glutamate neurotoxicity (decrease LDH release) [67,68]. N-methyl-D-aspartate (NMDA)-induced cell death in AF5 rat mesencephalic cell line was also prevented by THC (by CBR1 independent mechanism) (3 μM) [69]. THC exerted antioxidant and anti-apoptotic effects and significantly reduced dopaminergic cell death in culture induced by 1-methyl-4-phenylpyridinium (MPP+), lactacystin and paraquat. These effects of THC were blocked by peroxisome proliferator-activated receptor-gamma (PPARγ) antagonist [70]. Using differentiated human neuronal SY-SH5Y cells exposed to H<sub>2</sub>O<sub>2</sub> or amyloid-β1-42 (Aβ1-42) in the presence of Cu (II), Rajia et al. [71] reported

reduced ROS formation by cannabis extracts with high (72%) THC content.

#### 4.3 Animal Experiments

The effect of cannabis on oxidative stress is complex with both antioxidant and prooxidant effects being reported. Vella et al. [72] investigated the effect of 8 weeks administration of a small dose THC (0.15 mg/kg, daily, i.p.) in diabetic rats. There was marked decrease in serum MDA and NO in control rats. The increase in serum MDA in diabetic rats was significantly decreased by treatment with THC which also decreased IL-1β and increased IL-6 in serum. Coskun and Bolkent [73] found that rats treated with THC (3 mg/kg, ip.) daily for one week exhibited significant increase in MDA in the plasma. The erythrocyte GSH levels, plasma catalase or superoxide dismutase, however, were not changed. On the other hand, treatment of diabetic rats with THC resulted in significant decrease in plasma MDA. Moreover, erythrocyte GSH levels and plasma superoxide dismutase levels were significantly increased in the diabetic group treated with THC compared with the control diabetes group. The study showed that THC acted as antioxidant in diabetic but not in normal rats. Ebuchi and Solanke [74] treated rats with 25 mg/kg marijuana extract for two weeks. The authors reported significant increase in MDA and a decrease in GSH levels in rat brain and liver. The activities of the antioxidant enzymes superoxide dismutase and catalase decreased as well after treatment with the marijuana extract. Khadrawy et al. [75] investigated the effects of cannabis extract rich in THC in the model of reserpine induced depression in rats. *Cannabis sativa* extract (10 mg/kg THC, s.c.) given after 15 days of initiating reserpine and continued together with reserpine for another 15 days found to exacerbate the lipid peroxidation (MDA) in the cortex and hippocampus.

In the study of Kopjar et al. [76] rats were treated with a single THC dose of 7 mg/kg, orally. The authors reported significantly increased

thiobarbituric reactive substances (TBARS) in brain after 1 day of treatment with THC together with significantly elevated brain GSH Level by 37.5%. Serum TBARS decreased by 29.4%. Meanwhile, there was a significantly decreased superoxide dismutase activity in brain of THC-treated rats by 69.8% compared to controls. Kubiliene et al. [77] investigated the effect of marijuana extract on oxidative stress induced in mice brain by  $AlCl_3$ . The extract was given intragastrically at the dose of 1.6 mg/g for 21 days. Administration of only marijuana extract had no significant effect on levels of reduced glutathione in blood or MDA in brain and liver but significantly increased catalase activity. In  $AlCl_3$ -treated mice, however, cannabis alleviated the increase in MDA and the decline in catalase activity in brain and liver.

Other studies carried out in rodents using only marijuana or cannabis resin extracts showed a moderate though a significant decrease in brain MDA after treatment with cannabis at the dose of 20 mg/kg THC for 4 weeks [53,78]. Rats given subcutaneous (s.c.) injections of cannabis resin extract for 6 weeks showed significant increments in serum MDA. This was especially so for the lower doses of 5 or 10 mg/kg THC compared with the higher dose of 20 mg/kg [79]. Reduced glutathione was significantly increased in brain and serum by treatment with 20 mg/kg marijuana or cannabis resin extracts [49,54,78,80]. Moreover, brain superoxide dismutase activity and ascorbate level were shown to increase following treatment with cannabis extracts [81].

Nitric oxide is a free radical that when produced in excess can be neurotoxic via mechanisms such as inhibition of cytochrome, excitotoxicity, energy failure, and apoptosis [82]. These effects are mediated through interactions with  $O_2^{\cdot-}$  to form peroxynitrite or with  $O_2$  to form nitrogen oxides [83]. Studies showed significant decrease in brain nitric oxide in mice treated with only marijuana extract at 10, 15 or 20 mg/kg (expressed as THC) for 18-30 days [53,78] and in rats treated with cannabis resin extracts at the dose of 20 mg/kg THC for 6 weeks [79]. Moreover, in a study by Vella et al. [72] treatment with THC (15 mg/kg, i.p. for two months) caused a 24.6% decrease in serum nitric oxide. Inhibition of nitric oxide release might therefore account at least in part the ability of cannabinoids to protect neurons from excitotoxic injury [84].

## 5 Cannabis and Brain Energetic Metabolism

The mechanisms that underlie the detrimental effects of herbal cannabis on brain structure and function are not fully understood. Costa and Colleoni [85] suggested that inhibition of brain energetic metabolism and a low ATP production could be a mechanism by which long-term cannabis causes neuronal injury. The authors found that single i.p. administration of THC (10 mg/kg) in rats increased brain mitochondria oxidative phosphorylation via the cannabinoid CB1 receptor. Lipoperoxide levels in cerebral cortex were also increased possibly due to the increase in brain mitochondria oxygen uptake. In contrast, repeated administration of THC (10 mg/kg, twice daily for 4.5 days, i.p.) decreased the brain mitochondria oxygen consumption and uncoupled oxidative phosphorylation. In pig brain mitochondria in vitro, THC (also cannabidiol and anandamide) was shown to inhibit mitochondrial respiration [86].

The transcription factor, nuclear respiratory factor-2 (NRF-2), also known as GA-binding protein, mediates the expression of a number of nuclear-encoded mitochondrial proteins required for mitochondrial respiratory function and oxidative phosphorylation. NRF-2 is important for the control of mitochondrial biogenesis and functions. Loss of NRF-2 results in reduced mitochondrial mass, oxygen consumption and consequent decrease in ATP production and mitochondrial protein synthesis [87,88]. It has been shown in rats that treatment with cannabis extract for 6 weeks was associated with significant decrease in serum NRF-2, thereby, suggesting that cannabis could affect mitochondrial biogenesis and activity [79].

Studies in mice during infancy have also shown a detrimental and long-lasting effect for THC on brain bioenergetics. In this context, the repeated exposure of preadolescent healthy mice to THC (0.5 mg/kg) i.p. daily for 11 consecutive days disrupted the expression of mitochondrial proteins (complexes I-IV), and induced loss of membrane integrity occluding mitochondrial respiration [89]. In another study, the single administration of THC in 10-day-old mice (10 and 50 mg/kg) was found to affect the transcript levels of genes involved in neurotrophic and oxidative stress signaling 24 h after exposure i.e., decreased neurotrophic receptor Trkb transcript levels and increased Nrf2/Keap1 ratio in parietal cortex and hippocampus. The pro-apoptotic marker BAX was also increased in the frontal cortex [90]. It

was also found that administration of THC (1 or 5 mg/kg) daily to preadolescent mice caused disrupted expression of mitochondrial proteins (complexes I-IV), and induced loss of membrane integrity occluding mitochondrial respiration in hippocampal neurons. These effects of THC lasted more than 4 months [91].

Using positron emission tomography, Volko et al. [92] reported decreased cerebellar metabolism chronic marijuana abusers compared with normal subjects, which could explain the motor deficits in marijuana users. Rats treated with cannabis showed a significant decrease in brain glucose which might impair brain energetic and account for the effect of cannabis on memory functioning [78]. Other researchers found that small doses ( $\leq 0.01$  mg/kg) and low blood levels of THC ( $< 1$  ng/ml) were associated with increased glucose uptake especially in the hypothalamus. In contrast, higher doses ( $\geq 0.05$  mg/kg) and blood levels ( $> 10$  ng/ml) resulted in decreased glucose uptake, especially in the cerebellar cortex [93]. Cannabis (54 mg) given to healthy cannabis users either orally, through smoking (6.9%THC cigarette) or via inhalation of heated vaporized cannabis (Volcano®) caused significant increases in plasma ammonia concentrations which positively correlated with THC concentrations in blood. Experiments in mice indicated that THC (3 and 10 mg/kg, i.p.) significantly reduced striatal glutamine synthetase activity, and increased striatal ammonia concentration followed by significant increase in plasma ammonia. The THC-induced increase in brain ammonia might be neurotoxic [94].

## 6 Cannabis and Brain Inflammation

In rats, THC (0.5, 1.0 and 2.0 mg/kg, i.p.) was found to increase brain concentrations of prostaglandins E2 and F2 alpha [95] while repeated administration of THC (10 mg/kg) in mice increased brain cyclooxygenase-2 expression [96], suggesting that cannabis may cause brain inflammation. In female rats, chronic administration of increasing doses of THC during adolescence induces a persistent neuroinflammatory state in the adult prefrontal cortex. There were increased expression of the pro-inflammatory cytokine TNF- $\alpha$ , inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) and decreased anti-inflammatory cytokine interleukin-10. Inhibition of microglia activation inhibited during THC treatment prevented the neuroinflammatory state and attenuated short-term memory impairments in adulthood [97].

## 7 Conclusion

There is evidence from both human studies and animal research which strongly supports a detrimental effect for THC-rich cannabis on neuronal integrity. As for the role of oxidative stress, although cannabis users showed elevated blood levels of oxidative stress, in vitro and animal experiments were less conclusive. Clearly, there is a need for further research in this context.

### References:

- [1] World Drug Report 2020 (United Nations publication, Sales No. E.20.XI.6). <https://www.unodc.org/unodc/en/data-and-analysis/wdr2021.html>.
- [2] ElShohly MA. Chemical constituents of cannabis. In: Cannabis and cannabinoids. Pharmacology, Toxicology and Therapeutic Potential (Grotenhermen F, Russo E, eds). Haworth Press Inc, New York, 2002, pp. 27-36.
- [3] Brenneisen R. Chemistry and analysis of phytocannabinoids and other cannabis constituents. In: Forensic Science and Medicine: Marijuana and the Cannabinoids (ElSohly MA, ed). Humana, Totowa, 2006; pp. 17-49.
- [4] Radwan MM, ElSohly MA, El-Alfy AT, Ahmed SA, Slade D, Husni AS. et al. Isolation and Pharmacological evaluation of minor cannabinoids from high-potency *Cannabis sativa*. Journal of Natural Products 2015; 78(6): 1271-6.
- [5] Mechoulam R, Gaoni Y. The absolute configuration of delta-1-tetrahydrocannabinol, the major active constituent of hashish. Tetrahedron Letters 1967,12,1109-11.
- [6] Huestis MA. Cannabis (marijuana)—effects on human behavior and performance. Forensic Science Review 2002; 14:15.
- [7] Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids:  $\Delta^9$ -tetrahydrocannabinol, cannabidiol and  $\Delta^9$ -tetrahydrocannabivarin. British Journal of Pharmacology 2008; 153: 199-215.
- [8] Mechoulam R, Parker LA. The endocannabinoid system and the brain. Annual Review of Psychology 2013; 64:21-47.
- [9] Yenilmez F, Fründt O, Hidding U, Buhmann C. Cannabis in Parkinson's Disease: The Patients' View. Journal of Parkinson's Disease 2021;11(1):309-321.

- [10] Fiz J, Durán M, Capellà D, Carbonell J, Farré M. Cannabis use in patients with fibromyalgia: effect on symptoms relief and health-related quality of life. *PLoS One* 2011; 6:e18440.
- [11] Howard J, Anie KA, Holdcroft A, Korn S, Davies SC. Cannabis use in sickle cell disease: a questionnaire study. *British Journal of Haematology* 2005; 131:123–128.
- [12] Grill M, Hasenoehrl C, Storr M, Schicho R. Medical cannabis and cannabinoids: An option for the treatment of inflammatory bowel disease and cancer of the colon? *Medical Cannabis and Cannabinoids* 2018; 1: 28–35.
- [13] Ellis RJ, Toperoff W, Vaida F, van den Brande G, Gonzales J, Gouaux B. et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. *Neuropsychopharmacology* 2009; 34: 672–680.
- [14] Collin C, Ehler E, Waberszinek G, Alsindi Z, Davies P, Powell K. et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. *Neurological Research* 2010; 32:451–459.
- [15] Brady CM, Das Gupta R, Dalton C, Wiseman OJ, Berkley KJ, Fowler CJ. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. *Multiple Sclerosis* 2004; 10: 425–433.
- [16] Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. *Lancet* 2009; 374 (9698): 1383-1391.
- [17] Abdel-Salam OME. The harm of cannabis in adolescents. *Biomedical and Pharmacology Journal* 2019; 12(2): 495-498.
- [18] Arria AM, Caldeira KM, Bugbee BA, Vincent KB, O'Grady KE. The academic consequences of marijuana use during college. *Psychology of Addictive Behaviors* 2015; 29(3): 564–575.
- [19] Lorenzetti V, Hoch E, Hall W. Adolescent cannabis use, cognition, brain health and educational outcomes: A review of the evidence. *European Neuropsychopharmacology* 2020; 36: 169-180.
- [20] Bondallaz P, Favrat B, Chtioui H, Fornari E, Maeder P, Giroud C. Cannabis and its effects on driving skills. *Forensic Science International* 2016; 268: 92-102.
- [21] Arseneault L, Cannon M, Witton J, Murray RM. Causal association between cannabis and psychosis: examination of the evidence. *British Journal of Psychiatry*. 2004; 184: 110-117.
- [22] Wolff V, Armspach JP, Lauer V, Rouyer O, Bataillard M, Marescaux C, Geny B. Cannabis-related stroke: myth or reality? *Stroke* 2013; 44: 558-63.
- [23] Battistella G, Fornari E, Annoni JM, Chtioui H, Dao K, Fabritius M. et al. Long-term effects of cannabis on brain structure. *Neuropsychopharmacology* 2014; 39(9): 2041–2048.
- [24] Chan GC, Hinds TR, Impey S, Storm DR. Hippocampal neurotoxicity of Delta 9-tetrahydrocannabinol. *Journal of Neuroscience* 1998; 18: 5322-5332.
- [25] Sarafian TA, Magallanes JAM, Shau H, Tashkin D, Roth MD. Oxidative stress produced by marijuana smoke: an adverse effect enhanced by cannabinoids. *American Journal of Respiratory Cell and Molecular Biology* 1999; 20: 1286-1293.
- [26] Sarafian TA, Kouyoumjian S, Khoshaghideh F, Tashkin DP, Roth MD. D9-Tetrahydrocannabinol disrupts mitochondrial function and cell energetics. *American Journal of Physiology-Cell Physiology* 2003; 284: L298-L306.
- [27] Steel RW, Miller JH, Sim DA, Day DJ. Delta-9-tetrahydrocannabinol disrupts hippocampal neuroplasticity and neurogenesis in trained, but not untrained adolescent Sprague-Dawley rats. *Brain Research* 2014; 22: 1548:12-19.
- [28] Wolff V, Schlagowski AI, Rouyer O, Charles AL, Singh F, Auger C. et al. Tetrahydrocannabinol induces brain mitochondrial respiratory chain dysfunction and increases oxidative stress: a potential mechanism involved in cannabis-related stroke. *BioMed Research International* 2015; 2015:323706.
- [29] Zhu W, Friedman H, Klein TW.  $\Delta^9$ -tetrahydrocannabinol induces apoptosis in macrophages and lymphocytes: Involvement of Bcl-2 and caspase-1. *Journal of Pharmacology and Experimental Therapeutics* 1998; 286:1103-1109.
- [30] Downer E, Boland B, Fogarty M, Campbell V. Delta 9-tetrahydrocannabinol induces the apoptotic pathway in cultured cortical neurones via activation of the CB1 receptor. *NeuroReport* 2001; 12(18): 3973-8.
- [31] Downer EJ, Fogarty MP, Campbell VA. Tetrahydrocannabinol-induced neurotoxicity depends on CB1 receptor mediated c-Jun N-terminal kinase activation in cultured cortical neurons. *British Journal of Pharmacology* 2003; 140: 547-557
- [32] Gowran A, Campbell VA. A role for p53 in the regulation of lysosomal permeability by delta

- 9-tetrahydrocannabinol in rat cortical neurones: implications for neurodegeneration. *Journal of Neurochemistry* 2008; 105(4): 1513–24.
- [33] Scallet AC, Uemura E, Andrews A, Ali SF, McMillan DE, Paule MG. et al. Morphometric studies of the rat hippocampus following chronic delta-9-tetrahydrocannabinol (THC). *Brain Research* 1987; 436(1): 193-198.
- [34] Landfield PW, Cadwallader LB, Vinsant S. Quantitative changes in hippocampal structure following long-term exposure to delta 9-tetrahydrocannabinol: possible mediation by glucocorticoid systems. *Brain Research* 1988; 443(1-2): 47-62.
- [35] Abdel-Salam OME, Youness ER, Shaffee N. Biochemical, immunological, DNA and histopathological changes caused by *Cannabis Sativa* in the rat. *Journal of Neurology and Epidemiology* 2014; 2: 6-16. doi: <http://dx.doi.org/10.12974/2309-6179.2014.01.01.2>
- [36] O'Callaghan JP, Sriram K. Glial fibrillary acidic protein and related glial proteins as biomarkers of neurotoxicity. *Expert Opinion on Drug Safety* 2005; 4: 433-442.
- [37] Lopez-Rodriguez AB, Llorente-Berzal A, Garcia-Segura LM, Viveros MP. Sex-dependent long-term effects of adolescent exposure to THC and/or MDMA on neuroinflammation and serotonergic and cannabinoid systems in rats. *British Journal of Pharmacology* 2014; 171:1435-1447.
- [38] Abdel-Salam OME, Sleem AA, Youness ER, Omara EA. Identification of biomarkers for the detection of subtle brain injury after cannabis and/or tramadol administration. *Egypt. Egyptian Journal of Forensic Sciences* 2019; 9: 58. <https://doi.org/10.1186/s41935-019-0165-z>
- [39] van der Stelt M, Veldhuis WB, Bar PR, Veldink GA, Vliegthart JFG, Nicolay K. Neuroprotection by  $\Delta^9$ -tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity. *Journal of Neuroscience* 2001; 21(17):6475–6479.
- [40] Hayakawa K, Mishima K, Nozako M, Ogata A, Hazekawa M. et al. Repeated treatment with cannabidiol but not Delta9-tetrahydrocannabinol has a neuroprotective effect without the development of tolerance. *Neuropharmacology* 2007; 52: 1079-1087.
- [41] Abdel-Salam OME, Abdel Jaleel G, Morsy FA. Acute effects of *Cannabis sativa* on ischaemia/reperfusion injury in the rat brain. *Journal of Neurology and Epidemiology* 2017; 5: 25-34. doi: <https://doi.org/10.12974/2309-6179.2017.05.06>
- [42] Abdel-Salam OME, Sleem AA, Youness ER, Morsy F. Preventive effects of cannabis on neurotoxic and hepatotoxic activities of malathion in rat. *Asian Pacific Journal of Tropical Medicine* 2018; 11(4): 272-279.
- [43] Abdel-Salam OME, Youness ER, Khadrawy YA, Sleem AA. Acetylcholinesterase, butyrylcholinesterase and paraoxonase 1 activities in rats treated with cannabis, tramadol or both. *Asian Pacific Journal of Tropical Medicine* 2016; 9: 1066-1071.
- [44] Abdel-Salam OME, Khadrawy YA. The inhibition of serum cholinesterases by *Cannabis sativa* and/or tramadol. *Journal of Neurology Forecast* 2019; 2(1): 1005. doi: [10.1016/j.apjtm.2016.09.009](https://doi.org/10.1016/j.apjtm.2016.09.009).
- [45] Eubanks LM, Rogers CJ, Beuscher AE, Koob GF, Olson AJ, Dickerson TJ. et al. A molecular link between the active component of marijuana and Alzheimer's disease pathology. *Molecular Pharmacology* 2006; 3: 773-777.
- [46] Partland JM, Russo EB. Cannabis and cannabis extracts: greater than the sum of their parts? *Journal of Cannabis Research* 2001; 1: 103-132
- [47] Abdel-Salam OM, El-Shamarka ME-S, Omara EA. Modulation of neurobehavioral and biochemical alterations induced by aluminum chloride with *Cannabis sativa* extract. *Cell Biology: Research & Therapy* 2015; 4: 1.
- [48] Abdel-Salam OME, Sleem AA, Sayed MAEM, Khadrawy YA, Morsy FA. *Cannabis sativa* increases seizure severity and brain lipid peroxidation in pentylenetetrazole-induced kindling in rats. *Biomedical and Pharmacology Journal* 2018; 11(3): 1187-1197
- [49] Abdel-Salam OME, El-Shamarka M.E-S, Shaffee N, Gaafar AE-DM. Study of the effect of *Cannabis sativa* on liver and brain damage caused by thioacetamide. *Comparative Clinical Pathology* 2014; 23(3): 495-507.
- [50] Hien PP, Gortnizka H, Kraemer R. Rotenone-potential and prospect for sustainable agriculture. *Omonrice* 2003; 11: 83–92.
- [51] Alam M, Schmidt WJ. Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats. *Behavioural Brain Research* 2002; 136: 317–324.
- [52] Abdel-Salam OME. The rotenone model of parkinson's disease in studying the mechanisms of nigrostriatal cell death. *J. J. Pharma. Pharmacovigilance* 2015; 1(1): 007.
- [53] Abdel-Salam OME, Omara EA, El-Shamarka ME-S, Hussein JS. Nigrostriatal damage after

- systemic rotenone and/or lipopolysaccharide and the effect of cannabis. *Comparative Clinical Pathology* 2014; 23: 1343-58
- [54] Abdel-Salam OME, Nada SA, Salem NA, El-Shamarka M.E-S, Omara E. Effect of Cannabis sativa on oxidative stress and organ damage after systemic endotoxin administration in mice. *Comparative Clinical Pathology* 2014; 23 (4): 1069-1085.
- [55] Sies H. Oxidative stress: a concept in redox biology and medicine. *Redox Biology* 2015; 4: 180–183.
- [56] Halliwell B. Reactive oxygen species in living systems: source, biochemistry, and role in human disease. *American Journal of Medicine* 1991; 91: 14S–22S.
- [57] Floyd RA, Hensley K. Oxidative stress in brain aging. Implications for therapeutics of neurodegenerative diseases. *Neurobiology of Aging* 2002, 23, 795-807
- [58] Figueira TR, Barros MH, Camargo AA, Castilho RF, Ferreira JC, Kowaltowski AJ. et al. Mitochondria as a source of reactive oxygen and nitrogen species: from molecular mechanisms to human health. *Antioxidants & Redox Signaling* 2013; 18(16): 2029–74.
- [59] Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. *Nature* 2000; 408: 239-249.
- [60] Angelova PR, Abramov AY. Role of mitochondrial ROS in the brain: from physiology to neurodegeneration. *FEBS Letters*. 2018; 592: 692–702.
- [61] Toson EA. Impact of marijuana smoking on liver and sex hormones: Correlation with oxidative stress. *Nature and Science* 2011; 9(12): 76-87.
- [62] Mohamed A, Ibrahim KS, Mahdy-Abdallah H, Mohamed HA. Leukocyte telomere length in heavy tobacco and marijuana Egyptian smokers. *International Journal of PharmTech Research* 2016; 9(4):501-508.
- [63] Bayazit H, Selek S, Karababa IF, Cicek E, Aksoy N. Evaluation of oxidant/antioxidant status and cytokine levels in patients with cannabis use disorder. *Clinical Psychopharmacology and Neuroscience* 2017;15(3):237-242.
- [64] Bayazit H, Dulgeroglu D, Selek S. Brain-derived neurotrophic factor and oxidative stress in cannabis dependence. *Neuropsychobiology* 2020;79:186–190.
- [65] Bloomer RJ, Butawan M, Smith NJG. Chronic marijuana smoking does not negatively impact select blood oxidative stress biomarkers in young, physically active men and women. *Health* 2018; 10: 960-970.
- [66] Walker OS, Ragos R, Gurm H, Lapierre M, May LL, Raha S. Delta-9-tetrahydrocannabinol disrupts mitochondrial function and attenuates syncytialization in human placental BeWo cells. *Physiological Reports* 2020; 8:e14476.
- [67] Hampson AJ, Grimaldi M, Axelrod J, Wink D. Cannabidiol and (-) $\Delta^9$ -tetrahydrocannabinol are neuroprotective antioxidants. *Proceedings of the National Academy of Sciences of the United States of America* 1998; 95(14): 8268–8273
- [68] Hampson AJ, Grimaldi M, Lolic M, Wink D, Rosenthal R, Axelrod J. Neuroprotective antioxidants from marijuana. *Annals of the New York Academy of Sciences* 2000; 899:274-282.
- [69] Chen J, Lee CT, Errico S, Deng X, Cadet JL, Freeda WJ. Protective effects of  $\Delta^9$ -tetrahydrocannabinol against N-methyl-D-aspartate-induced AF5 cell death. *Brain Research Molecular Brain Research* 2005; 134(2): 215–225.
- [70] Carroll CB, Zeissler ML, Hanemann CO, Zajicek JP.  $\Delta^9$ -tetrahydrocannabinol ( $\Delta^9$ -THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease. *Neuropathology and Applied Neurobiology* 2012; 38: 535–547.
- [71] Raja A, Ahmadi S, de Costa F, Li N, Kerman K. Attenuation of oxidative stress by cannabinoids and cannabis extracts in differentiated neuronal cells. *Pharmaceuticals (Basel)* 2020; 13(11): 328.
- [72] Vella RK, Jackson DJ, Fenning AS.  $\Delta^9$ -tetrahydrocannabinol prevents cardiovascular dysfunction in STZ-diabetic Wistar-Kyoto rats. *BioMed Research International* 2017; 2017:7974149.
- [73] Coskun ZM, Bolkent S. Evaluation of  $\Delta^9$ -tetrahydrocannabinol metabolites and oxidative stress in type 2 diabetic rats. *Iranian Journal of Basic Medical Sciences* 2016; 19:154-158.
- [74] Ebuehi OAT, Solanke AS. *Cannabis sativa* and 'Karole' induced oxidative stress and altered brain serotonin in adult Wistar rats. *Nigerian Quarterly Journal Of Hospital Medicine* 2014; 24(3): 205-211.
- [75] Khadrawy YA, Abdel-Salam OME, Hosny EN. Cannabis exacerbates depressive symptoms in rat model induced by reserpine. *Behavioural Brain Research* 2017; 324: 41-50.

- [76] Kopjar N, Fuchs N, Žunec S, Mikolic A, Micek V, Kozina G, et al. DNA damaging effects, oxidative stress responses and cholinesterase activity in blood and brain of Wistar rats exposed to  $\Delta^9$ -tetrahydrocannabinol. *Molecules* 2019; 24: 1560.
- [77] Kubiliene A, Mickute K, Baranauskaite J, Marksa M, Liekis A, Sadauskiene I. The Effects of Cannabis sativa L. extract on oxidative stress markers in vivo. *Life* 2021; 11: 647.
- [78] Abdel-Salam OME, Salem NA, El-Shamarka ME-S, Ahmed NA-S, Hussein JS, El-Khyat ZA. Cannabis-induced impairment of learning and memory: Effect of different nootropic drugs. *EXCLI J.* 2013; 12: 193-214.
- [79] Abdel-Salam OME, Sleem AA, Youness FR, Omara EA. Oxidative stress in brain tissue and serum of rats treated with cannabis resin, tramadol or both. *ES Journal of Neurology* 2020; 1(1): 1003.
- [80] Abdel-Salam OME, El-Shamarka ME-S, Salem NA, Gaafar AE-DM. Effects of Cannabis sativa extract on haloperidol-induced catalepsy and oxidative stress in the mice. *EXCLI J* 2012; 11: 45-58.
- [81] El-Hiny MA, Abdallah DM, Abdel-Salam OME, Salem NA, El-Khyat ZA, Kenawy SA. Co-administration of nicotine ameliorates cannabis-induced behavioral deficits in normal rats: role of oxidative stress and inflammation. *Comparative Clinical Pathology* 2019; 28 (5): 1229-1236.
- [82] Brown GC. Nitric oxide and neuronal death. *Nitric Oxide* 2010; 23(3): 153–165.
- [83] Wink DA, Mitchell JB. Chemical biology of nitric oxide: Insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide. *Free Radical Biology and Medicine* 1999; 25(4–5): 434–456.
- [84] Kim SH, Won SJ, Mao XO, Jin K, Greenberg DA. Molecular mechanisms of cannabinoid protection from neuronal excitotoxicity. *Molecular Pharmacology* 2006; 69(3): 691-6
- [85] Costa B, Colleoni M. Changes in rat brain energetic metabolism after exposure to anandamide or delta9-tetrahydrocannabinol. *European Journal of Pharmacology* 2000; 395(1): 1–7.
- [86] Fišar Z, Singh N, Hroudová J. Cannabinoid-induced changes in respiration of brain mitochondria. *Toxicology Letters* 2014; 231(1): 62-71.
- [87] Scarpulla RC. Nuclear control of respiratory chain expression by nuclear respiratory factors and PGC-1-related coactivator. *Annals of the New York Academy of Sciences* 2008; 147: 321–334.
- [88] Yang ZF, Drumea K, Mott S, Wang J, Rosmarin AG. GABP transcription factor (nuclear respiratory factor 2) is required for mitochondrial biogenesis. *Molecular and Cellular Biology* 2014; 34(17): 3194-201.
- [89] Kolb B, Li Y, Robinson T, Parker LA. THC alters morphology of neurons in medial prefrontal cortex, orbital prefrontal cortex, and nucleus accumbens and alters the ability of later experience to promote structural plasticity. *Synapse* 2018; 72: e22020.
- [90] Philippot G, Forsberg E, Tahan C, Viberg H, Fredriksson R. A single  $\Delta^9$ -tetrahydrocannabinol (THC) dose during brain development affects markers of neurotrophyl, oxidative stress, and apoptosis. *Frontiers in Pharmacology* 2019; 10: 1156.
- [91] Beiersdorf J, Hevesi Z, Calvigioni D, Pyszkowski J, Romanov RA, Szodorai E. et al. Adverse effects of  $\Delta^9$ -tetrahydrocannabinol on neuronal bioenergetics during postnatal development. *JCI Insight* 2020; 5(23):e135418.
- [92] Volkow ND, Gillespie H, Mullani N, Tancredi L, Grant C, Valentine A. et al. Brain glucose metabolism in chronic marijuana users at baseline and during marijuana intoxication. *Psychiatry Research* 1996;67(1):29-38
- [93] Miederer I, Uebbing K, Röhrich J, Maus S, Bausbacher N, Krauter K. et al. Effects of tetrahydrocannabinol on glucose uptake in the rat brain. *Neuropharmacology* 2017; 117: 273-281.
- [94] Abulseoud OA, Zuccoli ML, Zhang L, Barnes A, Huestis MA, Lin DT. The acute effect of cannabis on plasma, liver and brain ammonia dynamics, a translational study. *Eur. Neuropsychopharmacology* 2017; 27(7): 679-690.
- [95] Bhattacharya SK. delta-9-tetrahydrocannabinol (THC) increases brain prostaglandins in the rat. *Psychopharmacology (Berl)* 1986; 90(4): 499-502.
- [96] Chen R, Zhang J, Fan N, Teng ZQ, Wu Y, Yang H, Tang YP, Sun H. et al.  $\Delta^9$ -THC-caused synaptic and memory impairments are mediated through COX-2 signalling. *Cell* 2013; 155: 1154–1165.
- [97] Zamberletti E, Gabaglio M, Grilli M, Prini P, Catanese A, Pittaluga A. et al. Long-term hippocampal glutamate synapse and astrocyte dysfunctions underlying the altered phenotype induced by adolescent THC treatment in male rats. *Pharmacological Research* 2016; 111: 459-470.

**Competing Interests:**

No competing interests to disclose.

**Contribution of Individual Authors to the Creation of a Scientific Article (Ghostwriting Policy)**

Abdel-Salam OME contributed solely to the manuscript.

**Sources of Funding for Research Presented in a Scientific Article or Scientific Article Itself**

This work is not supported by research grants.

**Creative Commons Attribution License 4.0 (Attribution 4.0 International, CC BY 4.0)**

This article is published under the terms of the Creative Commons Attribution License 4.0

[https://creativecommons.org/licenses/by/4.0/deed.en\\_US](https://creativecommons.org/licenses/by/4.0/deed.en_US)

**Publication Ethics for Researches Involving Human Subjects**

Not applicable.

**Publication Ethics for Researches Involving Animals**

Not applicable.

**Publication Ethics for Researches Involving Plants**

Not applicable.